近日，一则关于上海璎黎药业有限公司（以下简称"璎黎药业"）"大门被封"的消息在业内不胫而走。这 家曾因研发出高选择性PI3Kδ抑制剂林普利塞片（商品名：因他瑞，以下简称"林普利塞"）而声名鹊 起，并曾获得恒瑞医药2000万美元战略投资的明星Biotech（生物科技公司），如今却陷入窘境。 针对上述传闻，2月11日，璎黎药业发布声明称，公司所有经营活动均正常有序进行，各项研发、生 产、运营及服务工作均按计划稳步推进，并未出现任何影响公司正常运转的异常情形。 《每日经济新闻》记者（以下简称"每经记者"）实探璎黎药业位于上海漕河泾康桥商务绿洲的注册地址 后发现，公司大门及各处出入口均贴有封条，部分办公室已处于清空状态，现场还有两名工人正在包装 设备仪器等。一名璎黎药业工作人员向记者表示，公司确实正在整体搬迁，主要原因是"和房东有一些 租房上的纠纷，并不是企业经营有什么大的问题"。 此外，也有多位患者向记者反映，林普利塞这款"救命药"自2025年四季度起就已出现断供的情况，在多 地医院和药店均已无法采购，此前药企承诺的赠药活动也成了一张"空头支票"。 2月10日上午，每经记者再次来到璎黎药业办公地点。经由货运电梯来到 ...

Core Viewpoint - The sudden discontinuation of the Alzheimer's drug, 甘露特钠胶囊 (brand name "九期一"), by Green Valley Pharmaceutical has led to a crisis for patients relying on this medication, with reports of counterfeit drugs flooding the market as a result of the supply shortage [1][2][4]. Group 1: Drug Supply Crisis - The discontinuation of 甘露特钠胶囊 began in early May 2025 and peaked in June, leaving many families of Alzheimer's patients in desperate search for alternatives [1][2]. - Green Valley Pharmaceutical stated that the production halt was due to the expiration of the drug's registration certificate, which is currently awaiting review [4]. Group 2: Counterfeit Drug Market - The shortage of the legitimate drug has led to a surge in counterfeit products being sold online, with misleading names such as "同仁堂甘露特钠胶囊" and "甘露药食同源浓缩丸" appearing on e-commerce platforms [6][11]. - Prices for the legitimate drug have skyrocketed, with reports of it being sold for as much as 5000 yuan per box, compared to the original monthly cost of approximately 296 yuan after insurance [4][2]. Group 3: Brand Misuse and Legal Issues - The issue of brand misuse is not new for 同仁堂, which previously reported 65 instances of its name being used fraudulently in March 2025 [11]. - The sale of counterfeit drugs has been identified as a criminal offense, with a notable case in May 2024 involving a live-streaming fraud scheme that targeted older adults, resulting in a financial loss of 30.89 million yuan [13].